Qualigen Therapeutics, Inc. announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the Company's in-licensed genomic quadruplex (G4)-selective transcription inhibitor platform. Qualigen is developing this platform's lead compound, now called QN-302, as a potential treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2864 USD | +0.63% | -7.31% | -47.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.93% | 1.81M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.60% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+25.72% | 12.26B | |
+27.17% | 12.05B |
- Stock Market
- Equities
- QLGN Stock
- News Qualigen Therapeutics, Inc.
- Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302